Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
202.71
-2.65 (-1.29%)
Jan 7, 2026, 4:00 PM EST - Market closed
BDX Revenue
In the fiscal year ending September 30, 2025, Becton, Dickinson and Company had annual revenue of $21.84B with 8.24% growth. Becton, Dickinson and Company had revenue of $5.89B in the quarter ending September 30, 2025, with 8.33% growth.
Revenue (ttm)
$21.84B
Revenue Growth
+8.24%
P/S Ratio
2.67
Revenue / Employee
$303,333
Employees
72,000
Market Cap
57.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 21.84B | 1.66B | 8.24% |
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
| Sep 30, 2019 | 17.29B | 1.31B | 8.18% |
| Sep 30, 2018 | 15.98B | 3.89B | 32.17% |
| Sep 30, 2017 | 12.09B | -390.00M | -3.12% |
| Sep 30, 2016 | 12.48B | 2.20B | 21.41% |
| Sep 30, 2015 | 10.28B | 1.84B | 21.74% |
| Sep 30, 2014 | 8.45B | 392.00M | 4.87% |
| Sep 30, 2013 | 8.05B | 346.00M | 4.49% |
| Sep 30, 2012 | 7.71B | 124.00M | 1.64% |
| Sep 30, 2011 | 7.58B | 459.62M | 6.45% |
| Sep 30, 2010 | 7.12B | 137.66M | 1.97% |
| Sep 30, 2009 | 6.99B | 89.10M | 1.29% |
| Sep 30, 2008 | 6.90B | 614.78M | 9.79% |
| Sep 30, 2007 | 6.28B | 544.82M | 9.49% |
| Sep 30, 2006 | 5.74B | 397.18M | 7.44% |
| Sep 30, 2005 | 5.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BDX News
- 19 hours ago - Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In' - Forbes
- 1 day ago - Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst - Benzinga
- 3 days ago - BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - PRNewsWire
- 7 days ago - Best Dividend Aristocrats For January 2026 - Seeking Alpha
- 11 days ago - Best Dividend Kings: December 2025 - Seeking Alpha
- 21 days ago - BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry - PRNewsWire
- 21 days ago - The Magnificent 7 Are So Yesterday. These Are AI's Next Big Winners - Forbes
- 23 days ago - BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec - PRNewsWire